Monday, January 18, 2021
Home Latest Pharma-News U.S. FDA approved IN.PACT AV paclitaxel-coated balloon for the treatment of...

U.S. FDA approved IN.PACT AV paclitaxel-coated balloon for the treatment of Arteriovenous Fistula Lesions

Nov. 21, 2019: Medtronic  announced U.S. Food and Drug Administration (FDA) approval of the IN.PACT™ AV drug (paclitaxel)-coated balloon for the treatment of failing arteriovenous (AV) access in patients with end-stage renal disease (ESRD) undergoing dialysis. vessel restenosis limits the ability to use AV fistulae effectively.

Patients often undergo one to three maintenance procedures per year which can result in significant disruptions to critical hemodialysis care and increased costs to the healthcare system,so in order to minimize the the cost and maximizing a patient’s uninterrupted access to lifesaving dialysis care, Pivotal randomized trial results from the IN.PACT AV Access trial have shown IN.PACT AV DCB can extend the time between reinterventions by maintaining AV access site patency.

- Advertisement -

IN.PACT AV DCB, holds the technology from Medtronic’s IN.PACT™ Admiral™ platform, increases blood flow and reduces thickening of the vessel wall by delivering the proven anti-proliferative drug paclitaxel (penetrates deep into the vessel wall to prevent restenosis and  extend time between reinterventions). http://newsroom.medtronic.com/news-releases/news-release-details/medtronic-drug-coated-balloon-receives-us-fda-approval-treat

LEAVE A REPLY

Please enter your comment!
Please enter your name here

nineteen − 12 =

Most Popular

GSK presents positive efficacy data of dostarlimab at ASCO Gastrointestinal Cancers Symposium

January 16, 2021: "GlaxoSmithKline (GSK) plc announced updated data from GARNET cohort F evaluating dostarlimab in mismatch repair-deficient (dMMR) non-endometrial advanced solid...

Bharat Biotech signs agreement with Precisa Medicamentos for supply of ‘COVAXIN™’ to Brazil

January 12, 2020: "Bharat Biotech announced that it has signed an agreement with Precisa Medicamentos for the supplies of COVAXIN™ to Brazil.

What Is a Blockbuster Drug?

What Is a Blockbuster Drug? "Blockbuster drugs are those that generate at least $1 billion of revenue per...

Boehringer Ingelheim and Enara Bio join forces to discover Cancer Immunotherapies

January 12th, 2021: Boehringer Ingelheim and Enara Bio announced that they have entered into a strategic collaboration and licensing agreement to research...